MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Analysts' consensus is "Hold": 16 analysts cover MLTX (3 sell, 4 hold, 9 buy) with an average 12‑month price target of $23.08, and recent analyst moves include Rothschild raising its target to $40 and Oppenheimer to $35 while Goldman Sachs moved to a sell with a $10 target.
• Major insider sale: BVF Partners sold 3,750,000 shares at an average $16.79 (~$63.0M), cutting its stake by 78.3%; corporate insiders own 12.02% of the company while institutions hold about 93.85% of the stock.
• Shares trade near $17 (12‑month range $5.95–$62.75) with a market cap of ~$1.22B, strong liquidity ratios (quick/current ratio 9.27) but negative earnings (Q4 EPS -$0.92; analysts forecast -$1.79 for the year).

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has received a consensus recommendation of "Hold" from the sixteen analysts that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $23.0769.

Several brokerages recently issued reports on MLTX. Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $12.00 to $40.00 in a research note on Thursday, March 19th. Wolfe Research upgraded MoonLake Immunotherapeutics from an "underperform" rating to an "outperform" rating and boosted their price target for the company from $12.00 to $24.00 in a research note on Monday, March 23rd. Needham & Company LLC boosted their price target on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, February 23rd. The Goldman Sachs Group lowered MoonLake Immunotherapeutics from a "neutral" rating to a "sell" rating and upped their price objective for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. Finally, Oppenheimer upped their price objective on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Tuesday, February 24th.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the company's stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total value of $62,962,500.00. Following the sale, the director directly owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. This represents a 78.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 12.02% of the company's stock.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Large investors have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $509,000. Rhenman & Partners Asset Management AB grew its stake in shares of MoonLake Immunotherapeutics by 360.0% in the 3rd quarter. Rhenman & Partners Asset Management AB now owns 207,000 shares of the company's stock valued at $1,484,000 after purchasing an additional 162,000 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of MoonLake Immunotherapeutics by 22,387.5% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 84,553 shares of the company's stock valued at $606,000 after purchasing an additional 84,177 shares during the period. Boxer Capital Management LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $1,792,000. Finally, SG Americas Securities LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $126,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Trading Down 2.2%

Shares of MLTX opened at $16.98 on Tuesday. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -4.82 and a beta of 1.19. The stock's 50-day moving average price is $17.00 and its 200 day moving average price is $15.87.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.92). During the same period in the prior year, the business earned ($0.72) EPS. As a group, research analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.